Control Activitya | Inhibited Activityb | Treated Activitya | Inhibited Activityb | Activity Increasec | |
---|---|---|---|---|---|
pmol/min/mg | % | ||||
No Addition | 1 mM dbcAMP | ||||
Effect of dbcAMP Alone (n = 4) | |||||
Basal | 663.9 ± 31.1 | 888.2 ± 47.9 | 35 ± 11 | ||
Cilostamide-inhibited | 294.9 ± 17.4 | 369.0 ± 23.4 | 345.1 ± 28.5 | 543.2 ± 24.73-150 | 51 ± 18 |
[55%] | [61%] | ||||
Ro 20-1724-inhibited | 511.0 ± 19.2 | 152.9 ± 15.5 | 661.8 ± 52.0 | 226.5 ± 2.33-150 | 53 ± 16 |
[23%] | [26%] | ||||
IBMX-inhibited | 33.3 ± 6.4 | 630.7 ± 32.3 | 37.0 ± 3.4 | 851.2 ± 54.13-150 | 35 ± 10 |
[95%] | [96%] | ||||
4 mM Actinomycin D | 4 mM Actinomycin D + 1 mM dbcAMP | ||||
Effect of Actinomycin D Addition (n= 4) | |||||
Basal | 596.1 ± 38.2 | 692.7 ± 30.4 | 18 ± 11 | ||
Cilostamide-inhibited | 271.0 ± 12.4 | 325.1 ± 27.2 | 307.3 ± 12.1 | 385.4 ± 19.4 | 22 ± 14 |
[55%] | [56%] | ||||
Ro 20-1724-inhibited | 491.9 ± 24.1 | 104.2 ± 14.9 | 565.8 ± 24.2 | 126.9 ± 7.9 | 30 ± 19 |
[17%] | [22%] | ||||
IBMX-inhibited | 22.7 ± 2.4 | 573.5 ± 36.2 | 23.5 ± 2.2 | 669.2 ± 31.1 | 18 ± 11 |
[96%] | [97%] | ||||
100 mM Cycloheximide | 100 mM Cycloheximide +1 mM dbcAMP | ||||
Effect of Cycloheximide Addition (n = 4) | |||||
Basal | 750.5 ± 29.2 | 800.4 ± 48.3 | 7 ± 7% | ||
Cilostamide-inhibited | 405.1 ± 18.4 | 345.5 ± 20.3 | 426.9 ± 25.7 | 373.5 ± 38.6 | 9 ± 11% |
[46%] | [47%] | ||||
Ro 20-1724-inhibited | 597.7 ± 25.3 | 152.9 ± 16.6 | 618.3 ± 40.3 | 182.3 ± 12.9 | 24 ± 16% |
[20%] | [23%] | ||||
IBMX-inhibited | 37.3 ± 3.4 | 713.3 ± 29.6 | 37.5 ± 4.6 | 762.0 ± 46.1 | 7 ± 6% |
[95%] | [95%] |
Data in the first section are expressed as described in Table 2. Data in the other sections depict the influence of coapplication of actinomycin D or cycloheximide, respectively.
↵3-150 P < 0.05 between treated and control inhibited activities.